Announced details
Treatment of male stress urinary incontinence; regenerative medicine
The review body with which the Company’s subsidiary is proceeding with insurance coverage procedures
The Organization for Specialized Review of Medical Materials and Other Products of the Central Social Insurance Medical Council. Details regarding its location, representative, capital, year of establishment and business activities are Not disclosed.
Domestic marketing authorization for manufacture and sale obtained (registration number and validity period are Not disclosed)
The impact on consolidated results for the fiscal year ending March 2027 is currently under review. If any matters requiring disclosure arise, they will be disclosed promptly.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Cellution Cell Therapy Kit SUI |
| Counterparty | Central Social Insurance Medical Council, Organization for Specialized Review of Medical Materials and Other Products |
| Counterparty overview | The Organization for Specialized Review of Medical Materials and Other Products of the Central Social Insurance Medical Council. Details regarding its location, representative, capital, year of establishment and business activities are Not disclosed. |
| Relationship with the Company | The review body with which the Company’s subsidiary is proceeding with insurance coverage procedures |
| Applicable area | Treatment of male stress urinary incontinence; regenerative medicine |
| Registration number and expiry date | Domestic marketing authorization for manufacture and sale obtained (registration number and validity period are Not disclosed) |
| Impact on Business Performance | The impact on consolidated results for the fiscal year ending March 2027 is currently under review. If any matters requiring disclosure arise, they will be disclosed promptly. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The device was approved following deliberation by the Insurance Coverage Committee held in June 2026.